The latest progress report on global emissions reduction efforts showed there's a lot room for improvement, but the United States is doing its part.
The FDA rebuffed the company's appeal for a failed new drug application. What happens now?
Despite doubts over its lead drug candidate and the loss of a major partner, the company is forging ahead.
The gene-silencing specialist reported fiscal 2019 operating results and listed recent accomplishments.
A $9.7 billion deal and two failed takeover bids ushered in renewed enthusiasm for acquisitions in the pharmaceutical industry. What makes these stocks buyout candidates?
The company has halted the development of its lead drug candidate in one indication and terminated two other studies involving the compound.
The recent volatility hasn't been ideal, but it has certainly put the newly public company on the radar of investors.
The regenerative medicine company announced the pricing of a public stock offering.
The gene-editing pioneer announced the pricing of a public stock offering.
The pharma company announced the pricing of a public stock offering.
This early-stage biopharma is developing a promising gene-silencing pipeline that's beginning to turn heads.
A bearish analyst thinks the company's lead drug product is unlikely to live up to the hype.
The company's lead drug candidate earned Breakthrough Therapy designation from American regulators.
Illumina just proposed the nuclear option to earn regulatory approval for its merger and keep its biggest competitor at bay.
Arrowhead Pharmaceuticals and Assembly Biosciences headed into an important industry meeting with rising share prices. Only one left the meeting with momentum intact.
The title of a scientific abstract suggests that additional data from its lead pipeline program will bolster the case for regulatory approval.
The industry's most advanced drug candidate based on CRISPR gene editing has data from the first two patients.
The company's Neulasta biosimilar has generated $232 million in revenue in the first nine months of 2019, but its growth rate will slow soon.
Disappointing early sales results for its newest treatments, Rhopressa and Rocklatan, haven't shaken the company's confidence. Wall Street is a different story.
The small-cap biopharma inked a deal with a major pharmaceutical company, its second in three weeks.